The content is available as a PDF (237.6 KB).
. 2022 Jul 4;77:S715–S716. doi: 10.1016/S0168-8278(22)01748-2
TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
Eric Lawitz
, Rohit Loomba
, Douglas Denham
, Diana Chung
, Erin Quirk
, Lois Lee
, Tonya Marmon
, Kris Kowdley
Eric Lawitz
Find articles by Eric Lawitz
Rohit Loomba
Find articles by Rohit Loomba
Douglas Denham
Find articles by Douglas Denham
Diana Chung
Find articles by Diana Chung
Erin Quirk
Find articles by Erin Quirk
Lois Lee
Find articles by Lois Lee
Tonya Marmon
Find articles by Tonya Marmon
Kris Kowdley
Find articles by Kris Kowdley
Issue date 2022 Jul.
Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9252355